J&J launches once-daily Erleada for prostate cancer

Apr. 03, 2023 10:19 AM ETJohnson & Johnson (JNJ)By: Jonathan Block, SA News Editor1 Comment

Janssen Pharmaceuticals headquarters

Michael Vi/iStock Editorial via Getty Images

  • Johnson & Johnson's (NYSE:JNJ) Janssen unit has launched a new once-daily dose of Erleada (apalutamide), an androgen receptor inhibitor for prostate cancer, in the US.
  • Previously, the drug was only available in 60 mg tablets that typically had to be taken four times daily.
  • Erleada is approved for non-metastatic and metastatic castration-resistant prostate cancer.
  • Read why Seeking Alpha contributor JR Research recently upgraded J&J (JNJ) to a buy.

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.